STOCK TITAN

Protalix Biother - PLX STOCK NEWS

Welcome to our dedicated page for Protalix Biother news (Ticker: PLX), a resource for investors and traders seeking the latest updates and insights on Protalix Biother stock.

Protalix BioTherapeutics (NYSE: PLX) is a biopharmaceutical innovator leveraging its proprietary ProCellEx® plant cell-based technology to develop enzyme replacement therapies for rare diseases. This page provides investors and industry stakeholders with timely updates on clinical developments, regulatory milestones, and strategic partnerships.

Access comprehensive coverage of PLX's advancements in treating Gaucher disease, Fabry disease, and other rare conditions. Track updates across three key areas: clinical trial progress for pipeline candidates, commercial partnerships with global pharmaceutical leaders, and manufacturing innovations through the ProCellEx® platform.

Our curated news collection enables efficient monitoring of FDA submissions, earnings reports, and licensing agreements. Stay informed about the company's unique approach to cost-effective bioproduction and its expanding role in addressing unmet medical needs through plant-based protein expression systems.

Bookmark this page for direct access to verified press releases and objective analysis of Protalix's position within the competitive rare disease therapeutics market. Regular updates ensure you maintain current awareness of developments impacting both clinical outcomes and investment considerations.

Rhea-AI Summary

Protalix BioTherapeutics (NYSE American: PLX) has announced the full repayment of its 7.50% Senior Secured Convertible Promissory Notes, marking a significant milestone for the company. The repayment was financed entirely with available cash, resulting in Protalix becoming debt-free with no outstanding notes. This move has eliminated the potential equity overhang presented by the notes and strengthened the company's balance sheet.

CEO Dror Bashan highlighted that the company's financial discipline has led to a strong financial position, providing sufficient runway for planned ongoing operations. Protalix, a biopharmaceutical company specializing in recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, had previously relied on convertible notes for financing, with the total outstanding principal amount reaching $78.0 million at its peak.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.32%
Tags
none
-
Rhea-AI Summary

Protalix BioTherapeutics (NYSE American: PLX) reported Q2 2024 financial results and provided a business update. Key highlights include:

- Revenues from selling goods decreased 12% to $13.3 million

- License and R&D services revenue fell 99% to $0.2 million

- Net loss of $2.2 million ($0.03 per share) compared to net income of $19.3 million in Q2 2023

- Cash position of $45 million as of June 30, 2024

- Positive topline results from Phase I trial of PRX-115 for uncontrolled gout

- Preparations initiated for Phase II trial of PRX-115

The company's pipeline progress and strong balance sheet position it to repay convertible notes due September 2024 while maintaining operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.58%
Tags
-
Rhea-AI Summary

Protalix BioTherapeutics (NYSE American: PLX) has announced that it will release its financial results for the second quarter of 2024 on August 14, 2024. The company, which specializes in developing recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based protein expression system, will also provide a business and clinical update during a conference call with investors.

The conference call is scheduled for 8:30 a.m. EDT on August 14, 2024. Investors can join via toll-free numbers for US and Israeli participants, or through an international line. A webcast of the call will also be available, and a replay will be accessible for two weeks on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
Rhea-AI Summary

Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical firm, will host an in-person investor day on June 26, 2024, at the Lotte Palace New York Hotel. The event will begin at 8:30 a.m. EDT. Key opinion leaders, including Aleš Linhart of Charles University and Naomi Schlesinger of the University of Utah, will discuss the treatment landscapes for Fabry disease and uncontrolled gout, respectively. Special focus will be on clinical results for Elfabrio® (pegunigalsidase alfa) and PRX-115. Protalix's CEO, Dror Bashan, will also present a corporate overview. A live Q&A session will follow the presentations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
conferences clinical trial
-
Rhea-AI Summary

Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins via its ProCellEx® plant cell-based system, announced its participation at the 2024 BIO International Convention in San Diego, California. The convention, hosted by the Biotechnology Innovation Organization (BIO), is the largest industry event, gathering global biotech and biopharmaceutical executives. Dror Bashan, President and CEO of Protalix, will present on June 3, 2024, at 2:30 PM PDT in Theater 1, providing updates on corporate developments to industry leaders and investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
conferences
-
Rhea-AI Summary

Protalix BioTherapeutics, Inc. (PLX) reported financial results for Q1 2024, highlighting encouraging top-line results from the phase I clinical trial of its uricase candidate, PRX-115. The company plans to expand the trial into a phase II study. Despite a decrease in revenues, Protalix remains focused on research and development efforts to build its product pipeline. The company's cash position is strong, enabling it to repay convertible notes due in September 2024 and sustain ongoing operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12%
Tags
Rhea-AI Summary

Protalix BioTherapeutics, Inc. will announce its financial results for the first quarter of 2024 on May 10, 2024, along with a business and clinical update. The company focuses on developing and commercializing recombinant therapeutic proteins. Investors can join the conference call and webcast to discuss the results and recent developments. The call details are provided for easy access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
-
Rhea-AI Summary
Protalix BioTherapeutics, Inc. reports fiscal year 2023 financial results and business update, including regulatory approvals for Elfabrio and progress on PRX-115 clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.87%
Tags
-
Rhea-AI Summary
Protalix BioTherapeutics, Inc. (PLX) to release fiscal year 2023 financial results and business update on March 14, 2024. Conference call and webcast scheduled.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
Rhea-AI Summary
Protalix BioTherapeutics, Inc. (PLX) will present at the 2024 BIO CEO & Investor Conference on February 26, 2024. Management will give a corporate overview and participate in one-on-one meetings with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
conferences
Protalix Biother

NYSE:PLX

PLX Rankings

PLX Stock Data

203.67M
67.34M
13.7%
5.98%
6.86%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
Israel
HACKENSACK